author
seem
much
agreement
druglik
divers
defin
druglik
nondruglik
requir
type
refer
point
properti
distribut
commerci
avail
databas
examin
avail
chemic
directori
acd
seem
common
nondruglik
databas
pesticid
manual
use
altern
standard
nondruglik
annual
report
comput
chemistri
volum
q
elsevi
bv
issn
doi
right
reserv
compos
primarili
compound
design
caus
fatal
primari
organ
comprehens
medicin
chemistri
cmc
derwent
word
drug
index
wdi
modern
drug
data
report
mddr
among
commonli
use
druglik
databas
addit
phase
ii
compound
use
defin
druglik
compound
compound
druglik
index
calcul
base
upon
knowledg
deriv
known
drug
select
cmc
databas
properti
distribut
combinatori
compound
compar
drug
natur
product
larg
reflect
combinatori
chemistri
synthesi
constraint
fewer
chiral
center
complex
ring
system
distribut
ring
system
across
multipl
databas
describ
program
written
test
mddr
databas
identifi
candid
chemic
ring
replac
bioisoster
studi
databas
commerci
avail
drug
clear
divers
molecular
framework
ring
shape
extrem
low
shape
half
drug
databas
describ
frequent
occur
framework
divers
side
chain
provid
drug
molecul
quit
low
sinc
side
chain
account
side
chain
defin
druglik
exist
databas
lead
critic
chemistri
space
undefin
discoveri
opportun
unexplor
chemistri
space
limit
solut
popul
chemistri
space
nondruglik
marker
akin
way
point
gp
navig
system
multipl
filter
properti
may
incorpor
definit
druglik
lead
tradeoff
among
compound
properti
compound
intend
screen
optim
compound
properti
may
requir
type
multiparamet
optim
scheme
librari
design
fingerprint
algorithm
use
guid
divers
filter
also
need
employ
chemistri
synthesi
plan
process
good
qualiti
compound
made
differ
properti
rang
oral
inject
drug
summar
oral
drug
lower
mwt
fewer
hbond
donor
acceptor
rotat
bond
properti
profil
oral
drug
independ
year
drug
approv
market
degre
independ
target
polar
surfac
area
psa
one
definit
solvent
access
surfac
cover
oxygen
nitrogen
hydrogen
attach
oxygen
nitrogen
compound
progress
clinic
trial
steadi
chang
properti
eg
mwt
log
p
psa
declin
mwt
found
market
drug
reason
pattern
unclear
sinc
properti
relat
oral
absorpt
would
expect
reach
plateau
phase
ii
henc
select
pressur
properti
relat
oral
absorpt
disappear
pulmonari
drug
tend
higher
psa
pulmonari
permeabl
less
sensit
polar
hydrogenbond
function
anatom
make
sens
sinc
lung
close
compart
accumul
fluid
compound
termin
alveoli
must
clear
discrimin
antibacteri
nonantibacteri
activ
achiev
base
molecular
descriptor
overal
classif
rate
around
data
set
compound
use
variabl
select
log
p
chargedweight
neg
surfac
area
posit
surfac
area
heavi
atom
maximum
donor
delocaliz
threedimension
geometri
variat
littl
impact
discriminatori
perform
descriptor
druglik
effect
physic
mean
facilit
chemist
design
druglik
druglik
design
combinatori
librari
involv
use
rulebas
filter
like
rule
use
exclusionari
filter
remov
undesir
chemistri
function
captur
privileg
structur
inform
eg
natur
product
collect
retro
synthet
analysi
collect
bioactiv
molecul
natur
product
structur
featur
particularli
well
repres
cancer
chemotherapi
infecti
diseas
area
exclusionari
filter
describ
remov
reactiv
chemic
function
base
premis
compound
coval
chemistri
possibl
place
drug
discoveri
filter
also
necessari
remov
cross
reactiv
pool
compound
pool
procedur
singl
wellcharacter
compound
deliber
mix
speed
screen
compon
mixtur
must
neither
contain
structur
featur
caus
assay
fals
posit
must
contain
common
substructur
element
would
confus
deconvolut
activ
individu
compon
magnitud
number
poor
qualiti
screen
compound
emphas
report
million
uniqu
commerci
avail
compound
druglik
similar
result
found
virtual
screen
sarscov
proteas
commerci
avail
academ
compound
virtual
hit
million
compound
fail
three
druggabl
criteria
criteria
base
physic
chemic
structur
properti
provid
highqual
chemistri
subject
matter
support
nih
molecular
librari
small
molecul
repositori
initi
aim
collect
one
million
druglik
molecul
commerci
industri
govern
sourc
emphas
point
drug
must
contain
adequ
function
achiev
accept
receptor
interact
singl
filter
separ
druglik
nondruglik
compound
base
observ
nondrug
often
underfunction
privileg
structur
eg
benzodiazepin
recur
structur
activ
target
unrel
target
famili
view
molecular
filter
select
desir
chemistri
subject
matter
rich
sourc
screen
librari
recent
review
privileg
structur
featur
employ
combinatori
design
gpcr
librari
combinatori
synthesi
privileg
bicycl
structur
combinatori
synthesi
cyclic
peptid
homolog
model
suggest
parallel
common
privileg
gpcr
ligand
featur
complementari
deepli
buri
protein
featur
class
gpcr
group
target
famili
also
anoth
method
help
focu
particular
targetdirect
privileg
structur
idea
structur
similar
target
famili
member
bind
structur
similar
small
molecul
ligand
nmr
screen
help
identifi
privileg
protein
bind
element
albeit
smaller
size
although
strictli
speak
privileg
structur
privileg
structur
element
hydroxam
moieti
found
mani
metalloproteas
inhibitor
identifi
discern
privileg
structur
histor
larg
data
mine
exercis
howev
similar
recur
structur
motif
socal
molecular
anchor
describ
base
structurebas
ligand
bind
consider
rigid
small
molecul
ligand
molecular
anchor
incap
hydrophob
collaps
singl
noncollaps
ligand
conform
bind
protein
caviti
site
also
often
incap
hydrophob
collaps
concept
explain
frequent
occurr
noncollaps
spiro
structur
privileg
structuresmolecular
anchor
chemistri
design
principl
direct
difficult
goal
small
molecul
interfer
protein
protein
interact
via
alloster
interact
describ
intrigu
aspect
hypothesi
chemistri
emphasi
place
compound
core
capabl
interact
rel
fix
protein
hing
region
rather
elabor
lipophil
side
chain
attach
core
thermodynam
penalti
attend
ligand
bind
nonlowest
energi
protein
conform
suggest
screen
allow
slow
bind
adequ
assay
equilibr
time
implic
type
target
better
make
larger
number
smaller
librari
fewer
number
larg
librari
trend
smaller
librari
well
document
taken
extrem
approach
take
typic
dens
chemistri
space
coverag
tradit
combinatori
librari
targetori
synthesi
toward
direct
diversityori
synthesi
approach
chemistri
lead
gener
popul
divers
singl
molecul
broadli
chemistri
space
direct
cours
direct
less
effici
difficult
chemistri
focu
biolog
inform
content
rich
suggest
natur
product
combinatori
librari
start
point
chemic
content
rich
found
compound
produc
multicompon
reaction
mcr
chemic
transform
mani
four
compon
form
new
compound
singl
chemistri
reaction
step
ugi
reaction
carboxyl
acid
amin
aldehyd
isonitril
classic
exampl
theori
offer
effici
approach
synthesi
divers
compound
mcr
highthroughput
mode
current
suffer
signific
chemistri
limit
differ
druglik
leadlik
describ
lead
less
complex
paramet
drug
understand
medicin
chemistri
optim
almost
invari
increas
mwt
log
p
howev
structur
resembl
start
lead
drug
mark
implic
qualiti
lead
oppos
flaw
lead
far
like
lead
real
drug
leadlik
discoveri
also
refer
screen
small
molecul
librari
detect
weak
affin
high
micromolar
millimolar
rang
process
usual
lead
accept
chemistri
start
point
someth
els
ad
primari
screen
gener
multipl
small
molecul
bind
nonadjac
target
site
screen
small
mwt
singleton
howev
bind
two
compon
receptor
site
possibl
attest
discoveri
subnanomolar
ligand
term
click
chemistri
process
acetylen
azid
terminu
two
receptor
site
independ
bound
molecul
cycliz
singl
compound
two
compon
link
via
triazol
ring
filter
context
leadlik
small
molecul
screen
impli
control
properti
drug
start
point
eventu
result
process
rule
three
coin
small
molecul
fragment
screen
librari
mwt
log
p
hbond
donor
acceptor
rotat
bond
small
fragment
screen
nmr
xray
theori
method
capabl
detect
weak
interact
topic
filter
human
therapeut
drug
discoveri
receiv
numer
frequent
review
well
critic
fundament
medicin
chemistri
principl
neglect
rule
describ
four
simpl
paramet
associ
improv
prospect
oral
activ
poor
solubl
poor
permeabl
like
hbond
donor
express
sum
oh
nh
hbond
acceptor
express
sum
n
mwt
log
p
four
rule
rule
aris
filter
drug
discoveri
frequent
appear
cutoff
paramet
compound
class
natur
product
infecti
diseas
drug
etc
transport
affin
preval
except
rotat
bond
count
wide
use
filter
follow
find
greater
rotat
bond
correl
decreas
rat
oral
bioavail
mechanist
basi
rotat
bond
filter
unclear
sinc
rotat
bond
count
correl
vivo
clearanc
rate
rat
filter
reason
vitro
screen
viewpoint
sinc
ligand
affin
averag
decreas
kcal
two
rotat
bond
compound
index
medicin
chemistri
journal
show
recent
trend
toward
poor
properti
medicin
chemistri
compound
activ
nm
mw
log
p
log
sw
indic
compound
larger
hydrophob
less
solubl
compar
timetest
qualiti
lead
concept
import
compound
properti
eg
rule
complianc
beyond
potenc
wide
accept
although
notabl
occasion
except
oral
bioavail
compound
found
lie
well
outsid
rule
limit
rule
bypass
deliv
drug
nonor
rout
eg
pulmonari
intranas
dermal
answer
depend
much
dose
total
dose
mg
less
altern
deliveri
rout
begin
feasibl
howev
limit
current
clinic
candid
suffici
potenc
mgkg
rang
result
low
dose
find
potent
compound
seem
mostli
matter
luck
beyond
chemistrybas
featur
oral
drug
also
defin
biolog
target
strike
best
sell
mostli
oral
drug
ligand
protein
encod
small
subset
gene
consider
portion
target
oral
activ
drug
may
alreadi
discov
term
druggabl
genom
coin
describ
sever
restrict
chemistri
consider
relat
oral
activ
superimpos
possibl
biolog
target
space
scheme
separ
cn
noncn
activ
drug
wdi
allow
discoveri
simpl
paramet
relat
passiv
blood
brain
barrier
bbb
permeabl
predict
pglycoprotein
pgp
affin
pgp
transport
major
barrier
entri
compound
cn
appropri
determin
pgp
efflux
ratio
use
measur
compound
affin
pgp
howev
valu
filter
base
pgp
efflux
ratio
commonli
use
highthroughput
mode
colon
cell
permeabl
cell
cultur
assay
question
efflux
ratio
correl
vivo
rat
brain
penetr
psa
valu
less
tend
identifi
cn
activ
compound
simpl
set
two
rule
predict
cn
activ
n
number
nitrogen
oxygen
atom
molecul
less
equal
high
chanc
enter
brain
second
rule
predict
log
p
n
posit
compound
cn
activ
complex
commerci
avail
softwar
program
compar
abil
predict
cn
log
bbb
ratio
experiment
theoret
reason
support
belief
surfac
tension
measur
predictor
blood
brain
permeabl
predictor
absorpt
distribut
metabol
excret
adm
current
appear
use
global
model
limit
local
model
like
reflect
lack
qualiti
experiment
data
set
user
dissatisfact
may
result
unrealist
expect
given
magnitud
experiment
adm
error
addit
limit
scheme
separ
cn
noncn
compound
complex
bbb
compound
affin
transport
except
physicochem
base
filter
like
rule
problem
cn
sinc
estim
gene
select
express
bbb
encod
transport
protein
bbb
transport
current
known
psa
rather
simpl
model
commonli
use
paramet
predict
intestin
permeabl
rulebas
calcul
tpsa
fast
requir
structur
better
predict
intestin
permeabl
report
psa
partit
smaller
molecularli
base
compon
use
molecular
surfac
properti
compound
select
world
health
organ
list
essenti
drug
could
classifi
accuraci
permeabl
solubl
use
six
bin
scheme
similar
fda
biopharmaceut
classif
system
pharmacokinet
paramet
includ
permeabl
also
gener
filter
ligand
affin
predict
volsurf
softwar
analysi
small
druglik
molecul
suggest
filter
log
enhanc
probabl
good
permeabl
collect
commerci
avail
drug
use
determin
exclus
criteria
differenti
poorli
absorb
drug
wellabsorb
drug
similar
rule
mwt
log
p
associ
better
absorb
compound
except
mwt
criteria
compound
sugar
moieti
high
atom
weight
larg
cyclic
structur
suggest
involv
absorpt
biolog
transport
system
base
intestin
absorpt
drug
druglik
compound
rat
signific
relationship
rat
intestin
absorpt
extrapol
human
absorpt
drug
hydrogenbond
acid
basic
poor
aqueou
solubl
wide
spread
problem
combinatori
librari
oppos
poor
intestin
permeabl
much
less
problem
onehalf
poor
solubl
due
larg
sizelipophil
log
p
identifi
compound
poor
aqueou
solubl
due
crystal
pack
consider
comput
filter
melt
point
experiment
indic
crystal
pack
aqueou
solubl
decreas
rise
melt
point
melt
point
avail
valuabl
paramet
solubl
predict
progress
toward
comput
melt
point
suggest
success
qualit
rank
compound
lowmedium
highsolubl
bin
descriptor
hydrophil
polar
partial
atom
charg
molecular
rigid
found
posit
correl
melt
point
wherea
nonpolar
atom
high
flexibl
within
molecul
neg
correl
volum
distribut
vd
key
pharmacokinet
paramet
low
vd
less
lkg
identifi
drug
resid
plasma
compart
vd
greater
lkg
identifi
compound
access
tissu
compart
outsid
plasma
compart
eg
mani
cn
drug
vd
valu
ten
higher
recent
develop
comput
approach
predict
vd
neutral
basic
drug
work
well
vivo
experiment
measur
provid
accur
experiment
compound
log
pk
avail
predict
retain
comput
log
pk
use
accuraci
declin
somewhat
approxim
drug
oxid
cytochrom
cyp
famili
enzym
henc
decis
tree
cyp
substrat
affin
import
describ
characterist
cyp
substrat
lipophil
mwt
hydrogenbond
potenti
govern
select
toward
individu
cyp
compound
mark
propens
bind
multipl
target
socal
nuisanc
compound
littl
valu
drug
discoveri
compound
experiment
identifi
bind
fetal
calf
serum
long
known
compound
could
identifi
reproduc
activ
ht
screen
could
optim
chemistri
compound
often
appear
activ
multipl
screen
biolog
relationship
analysi
promiscu
compound
ht
hit
led
conclus
colloid
aggreg
nm
size
rang
respons
appar
ht
screen
activ
due
biophys
effect
rather
due
normal
ligand
receptor
affin
henc
hit
unoptimiz
chemistri
promiscu
aggreg
effect
found
among
kinas
inhibitor
wide
use
biolog
screen
emphas
import
exclusionari
filter
prevent
wast
biolog
research
time
test
compound
flaw
properti
aggreg
phenomenon
found
among
known
drug
albeit
test
high
nonphysiolog
concentr
predict
model
develop
filter
also
appli
agrochem
compar
drug
intend
human
use
agrochem
tend
fewer
hydrogenbond
donor
agrochem
screen
comput
intens
surfac
area
paramet
offer
advantag
rule
analog
druglik
agrochemlik
larg
compound
collect
explor
use
support
vector
machin
svm
studi
svm
perform
better
neural
network
